Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.

Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J.

PLoS One. 2013 Oct 16;8(10):e77731. doi: 10.1371/journal.pone.0077731. eCollection 2013.


Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.

PLoS One. 2013 Oct 4;8(10):e76551. doi: 10.1371/journal.pone.0076551. eCollection 2013.


Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.

Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J.

BMC Cancer. 2012 Mar 21;12:101. doi: 10.1186/1471-2407-12-101.


Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma.

Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, Chung JY, Metaferia BB, Badgett TC, Johansson P, Wei JS, Hewitt SM, Khan J.

Cancer Biol Ther. 2009 Dec;8(24):2386-95. Epub 2009 Dec 27.


Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

Taylor JG 6th, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J.

J Clin Invest. 2009 Nov;119(11):3395-407. doi: 10.1172/JCI39703. Epub 2009 Oct 5.


microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies.

Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, Cheuk AT, Smith MA, Houghton P, Morton C, Khan J.

Clin Cancer Res. 2009 Sep 1;15(17):5560-8. doi: 10.1158/1078-0432.CCR-08-3287. Epub 2009 Aug 25.


Anti-tumor immunity in a model of acute myeloid leukemia.

Cheuk AT, Wells JW, Chan L, Westwood NB, Berger SA, Yagita H, Okumura K, Farzaneh F, Mufti GJ, Guinn BA.

Leuk Lymphoma. 2009 Mar;50(3):447-54. doi: 10.1080/10428190802653776.


The MYCN oncogene is a direct target of miR-34a.

Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, Khan J.

Oncogene. 2008 Sep 4;27(39):5204-13. doi: 10.1038/onc.2008.154. Epub 2008 May 26.


Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.

Cheuk AT, Guinn BA.

Front Biosci. 2008 Jan 1;13:2022-9. Review.


Development of a whole cell vaccine for acute myeloid leukaemia.

Cheuk AT, Chan L, Czepulkowski B, Berger SA, Yagita H, Okumura K, Farzaneh F, Mufti GJ, Guinn BA.

Cancer Immunol Immunother. 2006 Jan;55(1):68-75. Epub 2005 Oct 27. Review.


Role of 4-1BB:4-1BB ligand in cancer immunotherapy.

Cheuk AT, Mufti GJ, Guinn BA.

Cancer Gene Ther. 2004 Mar;11(3):215-26. Review.


Characterization of additional genetic events in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion: a molecular cytogenetics study.

Ma SK, Wan TS, Cheuk AT, Fung LF, Chan GC, Chan SY, Ha SY, Chan LC.

Leukemia. 2001 Sep;15(9):1442-7.


Supplemental Content

Loading ...
Support Center